<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> are at high risk for developing <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular diseases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Traditional medicines for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, such as <z:chebi fb="0" ids="26831">sulfonylureas</z:chebi>, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>, and insulin have <z:chebi fb="105" ids="17234">glucose</z:chebi> lowering effects; however, they also increase the frequency of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> and/or body weight and thus may cancel out the benefits of <z:chebi fb="105" ids="17234">glucose</z:chebi> lowering on the development of <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In contrast, the recently developed glucagon like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1-based therapy using glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 receptor <z:chebi fb="4" ids="48705">agonists</z:chebi> or dipeptidyl peptidase-4 inhibitors has numerous beneficial effects in the management of <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> with less risk of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> and <z:mp ids='MP_0005456'>weight gain</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1-based therapy also lowers blood pressure and blood <z:chebi fb="23" ids="18059">lipids</z:chebi> and thus may prevent progression of <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 receptors are abundantly expressed in vascular cells such as endothelial cells, monocyte/macrophages and smooth muscle cells </plain></SENT>
<SENT sid="5" pm="."><plain>Recent studies suggest that the anti-inflammatory and vasodilatory properties of glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 signaling on endothelial cells, its anti-inflammatory effect on macrophages and anti-proliferative effects on smooth muscle cells may halt <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Although large clinical trials are required to confirm these beneficial effects, glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1-based therapy could provide both <z:chebi fb="105" ids="17234">glucose</z:chebi> lowering and protection against <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular diseases</z:e> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>